Span Biotronics Private Limited - Due diligence report

A 360° intelligence report on Arkray: trust score, financial health, credit view, compliance, directors, growth and distress signals - gener…

2006-11-08 Mumbai, Maharashtra Strike Off Unlisted Active Compliant
Share
Connect MCP
SB Span Biotronics Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Arkray — 360° Intelligence Report

Generated from MCA filings & public records
54/100
Trust Score
Moderate

Arkray is assessed as Moderate with a Trust Score of 54/100. Arkray is a private limited indian non-government company incorporated in 2006, operating in the Healthcare sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and high financial risk profile.

Report generated on 16 Aug 2026 from the latest processed filings. Span Biotronics Private Limited snapshot & full profile →

Financial Health › Weak
Overall Assessment CautionWeakNeutralGoodStrong Neutral
Compliance › Weak

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
54/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
43/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
30/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
35/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 4 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 43/100 Caution Indicated
  • Company status is "Strike Off" - not Active.
  • Balance sheet slightly behind (Mar 2024).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
RYOSUKE KAMEYAMA 01234567 Director 01/04/2018 6 yrs Approved
YUKITOSHI YAO 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2017 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Arkray Healthcare Private Limited
Subsidiaries
-
Group entities
-
Capital events
0 allotment(s) · 2 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Arkray Healthcare Private Limited Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 40 · Distress 35
Growth signals & trust indicators
Operating for 19+ years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Adverse company status: Strike Off.
Compliance score is weak (43/100).
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence44/100
Caution indicated
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment40/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view40/100
Limited indicators at present
Growth quality and scalability through an investor lens.
  • No clear growth signals in the filed years.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
23 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
20 Sep 2021
Director ceased
RYOSUKE KAMEYAMA
05 Jul 2021
Director ceased
KENJI YOSHIHARA
06 May 2021
Director appointed
RYOSUKE KAMEYAMA (Director)
01 Mar 2021
Director ceased
TADASHI INOUE
31 Mar 2016
Share transfer (FY 2016)
1.00000000 shares to KIYOSHI TADASHI
29 Sep 2015
Director ceased
YUKITOSHI YAO
31 Mar 2015
Share transfer (FY 2015)
10000.00000000 shares to Arkray Healthcare Private Limited Arkray Healthcare Private Limited
Director ceased
PRADIPKUMAR KESHAVLAL DESAI
Director ceased
SUJATA VIRAL DESAI
13 Mar 2015
Director appointed
YUKITOSHI YAO (Director)
05 Mar 2015
Director ceased
VIRAL PRADIPKUMAR DESAI
Director ceased
SANJAY NATWARLAL MEHTA
08 Nov 2006
Incorporated
Registered with Roc Mumbai
10

Key Observations

Auto-generated from the data above
Revenue declined 38% over the last 3 financial year(s).
Debt-to-equity stands at 1.42 - leverage worth monitoring.
Net worth is positive.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2017 annual return.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Scan Surgical Industries Private Limited U33110MH1988PTC048824 Mumabi, Maharashtra, India
Riva Plastics Private Limited U15549GJ1984PTC007015 Surat, Gujarat, India
Orion Medicare Pvt Ltd U24231DL2005PTC143026 New Delhi, Delhi, India
Embrace Innovations U74900KA2010PTC052267 Bangalore, Karnataka, India
Goa Medimachining Private Limited U33110GA2011PTC006679 Ponda, Goa, India
Jodhana Medical And Research Centre Ltd U85110MH1992PLC068793 Mumbai, Maharashtra, India
Medifurn Systems Private Limited U33119PY2003PTC001740 Pondicherry, Pondicherry, India
Eos International Private Limited U33111KA2013PTC068363 Bangalore, Karnataka, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Arkray before audits and certifications: compliance score 43/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Arkray: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Enhanced diligence advised. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Limited indicators at present. Growth score 40/100, margin trends, ownership structure and peer set for Arkray - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Caution indicated. Trust score 54/100, distress signals and MSME payment-delay disclosures - know whether Arkray pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Arkray - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Arkray an active company?

Arkray has MCA status “Strike Off” with a compliance score of 43/100 (Caution Indicated).

Is Arkray financially healthy?

Arkray has a Financial Health Score of 30/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Arkray?

Its overall Trust Score is 54/100 (Moderate). Vendor verdict: Caution indicated. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Arkray?

The ultimate holding entity is Arkray Healthcare Private Limited. 2 active director(s) are on record.

Does Arkray have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Arkray up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 43/100 (Caution Indicated).

Is it risky to lend to Arkray?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.